admin

About admin

This author has not yet filled in any details.
So far admin has created 6 blog entries.

AffyImmune Therapeutics Announces IND Approval for a First-in-Man Trial of Affinity-Tuned CAR T cells for Patients with Advanced, Refractory Thyroid Cancer

Natick, MA, October 30, 2019—AffyImmune Therapeutics, an emerging leader in CAR-T therapies, today announced FDA approval of the company’s investigational new drug (IND) application for AIC100, an affinity-tuned CAR T cell that received Orphan designation for advanced thyroid cancer. The trial: Phase I study of AIC100 in relapsed and or refractory [...]

By |2020-07-09T23:27:20+00:00January 16th, 2020|Recent News|Comments Off on AffyImmune Therapeutics Announces IND Approval for a First-in-Man Trial of Affinity-Tuned CAR T cells for Patients with Advanced, Refractory Thyroid Cancer
Read More

Event

Event info to go here.Leo in vitae turpis massa sed elementum tempus egestas sed. Morbi leo urna molestie at elementum eu. Ornare aenean euismod elementum nisi quis eleifend quam adipiscing. Enim diam vulputate ut pharetra sit amet aliquam. Maecenas sed enim ut sem viverra. Ultricies mi eget mauris pharetra et. Cursus [...]

By |2020-01-23T22:27:18+00:00January 8th, 2020|Uncategorized|Comments Off on Event
Read More

This will be Recent News

Text would go here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ipsum consequat nisl vel pretium lectus quam. Sollicitudin ac orci phasellus egestas. Eget est lorem ipsum dolor. Ut tristique et egestas quis ipsum. Iaculis at erat pellentesque adipiscing [...]

By |2020-01-20T16:01:03+00:00January 8th, 2020|Uncategorized|Comments Off on This will be Recent News
Read More

AffyImmune Therapeutics Inc. | 12 Michigan Drive, Natick, MA 01760 | (617) 699-1965
General inquiries | Partnering inquiries | Clinical trials inquiries | Career inquiries

Copyright 2020 Affyimmune | All Rights Reserved